Eli Lilly (LLY)

All three ETFs complement each other well in a portfolio.

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are a handful of bargains and pretenders.

SpaceX recently completed a record IPO.

The weight loss tailwind isn't about to come to a halt.

Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.

As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.

Why settle for puny yields when you can buy these monster dividend stocks?

These stocks are no-brainer buys.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

The top stocks are showing relative strength. Two are defensive growth plays.

There are still great opportunities in an otherwise volatile market.

Eli Lilly holds a dominant market share in the weight loss treatment category.

The pharma titan is expanding into new markets.

Eli Lilly is a leader in the revolutionary GLP weight-loss market. Lilly was one of 28 stocks new to best stock lists Friday.

Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's commit...

The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish.

Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.

These aren't for the faint of heart.

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.